Global Bioenergies SA

ENXTPA:ALGBE Stock Report

Market Cap: €14.8m

Global Bioenergies Past Earnings Performance

Past criteria checks 0/6

Global Bioenergies has been growing earnings at an average annual rate of 8.5%, while the Chemicals industry saw earnings growing at 7.4% annually. Revenues have been growing at an average rate of 48.6% per year.

Key information

8.5%

Earnings growth rate

25.9%

EPS growth rate

Chemicals Industry Growth10.4%
Revenue growth rate48.6%
Return on equity-159.3%
Net Margin-1,514.5%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Global Bioenergies SA's (EPA:ALGBE) Intrinsic Value Is Potentially 60% Above Its Share Price

Sep 18
Global Bioenergies SA's (EPA:ALGBE) Intrinsic Value Is Potentially 60% Above Its Share Price

Does Global Bioenergies (EPA:ALGBE) Have A Healthy Balance Sheet?

Jun 21
Does Global Bioenergies (EPA:ALGBE) Have A Healthy Balance Sheet?

Is Global Bioenergies (EPA:ALGBE) Using Debt Sensibly?

Jun 28
Is Global Bioenergies (EPA:ALGBE) Using Debt Sensibly?

Global Bioenergies (EPA:ALGBE) Has Debt But No Earnings; Should You Worry?

Oct 11
Global Bioenergies (EPA:ALGBE) Has Debt But No Earnings; Should You Worry?

Does Global Bioenergies (EPA:ALGBE) Have A Healthy Balance Sheet?

Oct 25
Does Global Bioenergies (EPA:ALGBE) Have A Healthy Balance Sheet?

Global Bioenergies (EPA:ALGBE) Shareholders Have Enjoyed An Impressive 187% Share Price Gain

Mar 20
Global Bioenergies (EPA:ALGBE) Shareholders Have Enjoyed An Impressive 187% Share Price Gain

Revenue & Expenses Breakdown

How Global Bioenergies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ENXTPA:ALGBE Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-7100
31 Mar 242-8100
31 Dec 233-9110
30 Sep 234-9100
30 Jun 234-10130
31 Mar 232-11140
31 Dec 221-12140
30 Sep 221-11130
30 Jun 221-10130
31 Mar 221-11130
31 Dec 211-12140
30 Sep 210-12160
30 Jun 210-12140
31 Mar 210-11140
31 Dec 200-11130
30 Sep 200-13130
30 Jun 200-12130
31 Mar 200-12130
31 Dec 190-14130
30 Sep 191-13100
30 Jun 191-12130
31 Mar 191-13130
31 Dec 181-14140
30 Sep 181-16150
30 Jun 180-17160
31 Mar 180-16150
31 Dec 170-14140
30 Sep 170-11130
30 Jun 171-10130
31 Mar 171-10130
31 Dec 161-11140
30 Sep 160-11160
30 Jun 161-11120
31 Mar 161-11120
31 Dec 151-10120
30 Sep 151-9110
30 Jun 151-8100
31 Mar 152-7100
31 Dec 142-690
30 Sep 142-69-1
30 Jun 142-68-1
31 Mar 141-67-1
31 Dec 131-57-1

Quality Earnings: ALGBE is currently unprofitable.

Growing Profit Margin: ALGBE is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ALGBE is unprofitable, but has reduced losses over the past 5 years at a rate of 8.5% per year.

Accelerating Growth: Unable to compare ALGBE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALGBE is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-8.2%).


Return on Equity

High ROE: ALGBE has a negative Return on Equity (-159.25%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies